Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01427504 · ClinicalTrials.gov registry record · NA

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

A NA study of HIV and Hepatitis C, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
26
Enrollment target
1
Study location

NCT01427504: Completed NA study of HIV and Hepatitis C, sponsored by University of Colorado, Denver.

NCT01427504 is a NA study of HIV and Hepatitis C that has completed, run by University of Colorado, Denver. The registered enrollment target is 26 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01427504, a NA study of HIV and Hepatitis C, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine. The investigators believe that etravirine's drug concentrations will be increased when administered in combination with boceprevir. Additionally, the investigators believe that boceprevir and etravirine are safe when administered alone or in combination.

Primary Outcome

Determine boceprevir area-under-the concentration time curve (AUC) when administered alone.

Conditions Studied

Interventions

  • DRUG boceprevir; etravirine

Study Locations (1)

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2011-08
Est. Completion 2012-03
Phase NA
University of Colorado, Denver

1,283 total trials

What the finished NCT01427504 record still lists

NCT01427504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which boceprevir; etravirine is the first listed.

NCT01427504 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT01427504 about?

NCT01427504 is a clinical study titled "Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers". The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine. The investigators believe that etravirine's drug concentrations will be increased when administered in combination with boceprevir. Additionally, the investigators believ...

What is the current status of trial NCT01427504?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2011-08. Estimated completion is 2012-03.

What conditions does trial NCT01427504 study?

This clinical trial studies the following conditions: HIV, Hepatitis C.

What interventions are being tested in trial NCT01427504?

The interventions under investigation include: boceprevir; etravirine (DRUG).

Who is sponsoring clinical trial NCT01427504?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01427504 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01427504's enrollment target sits among peer trials

26 277th of 303 higher than 27 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01427504, the US trial registry maintained by the National Library of Medicine. NCT01427504 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.